Phase II study of 5‐fluorouracil/leucovorin for pediatric patients with malignant solid tumors

Charles B. Pratt, William H. Meyer, Nanna Howlett, Edwin C. Douglass, Laura C. Bowman, Debbie Poe, Kevin Mounce, Larry E. Kun, Janet A. Houghton

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background. 5‐Fluorouracil (5‐FU) activity for various carcinomas of adults has been enhanced through the synergistic effect of leucovorin. Few pediatric studies of 5‐FU in pediatric patients have been previously reported. Methods. Fifty‐eight patients were treated with a 4‐hour infusion of leucovorin, 400 mg/m2, administered daily for 5 days every 3‐4 weeks. 5‐Fluorouracil was administered by bolus injection 1 hour into each leucovorin infusion. Eleven adolescent patients with colorectal carcinoma, Stage 3 or 4, were treated with therapeutic intent, and other patients with a variety of drug‐resistant pediatric solid neoplasms received similar treatment. Results. Patients with measurable disease of colorectal carcinoma responded favorably to 5‐FU/leucovorin. Stable disease activity was seen with other tumor types. Specifically, there were no objective responses in 12 patients with Ewing's Sarcoma or 11 with osteosarcoma. There were 4 deaths in this study from causes related to toxicity. Nonfatal grade 3/4 toxicities included mucositis, rash, myelosuppression, nausea, vomiting, diarrhea, and infection. Conclusion. The authors do not plan further evaluation of 5‐FU/leucovorin in additional pediatric patients with colon cancer or other heavily pretreated malignant solid tumors and are presently treating their patients with colon carcinoma with 5‐FU/leucovorin/interferon‐α2a.

Original languageEnglish (US)
Pages (from-to)2593-2598
Number of pages6
JournalCancer
Volume74
Issue number9
DOIs
StatePublished - Jan 1 1994

Fingerprint

Leucovorin
Pediatrics
Neoplasms
Colorectal Neoplasms
Carcinoma
Mucositis
Ewing's Sarcoma
Osteosarcoma
Exanthema
Colonic Neoplasms
Nausea
Vomiting
Diarrhea
Colon
Injections
Therapeutics
Infection

Keywords

  • 5‐Fluorouracil
  • childhood tumors
  • colon carcinoma
  • leucovorin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pratt, C. B., Meyer, W. H., Howlett, N., Douglass, E. C., Bowman, L. C., Poe, D., ... Houghton, J. A. (1994). Phase II study of 5‐fluorouracil/leucovorin for pediatric patients with malignant solid tumors. Cancer, 74(9), 2593-2598. https://doi.org/10.1002/1097-0142(19941101)74:9<2593::AID-CNCR2820740930>3.0.CO;2-C

Phase II study of 5‐fluorouracil/leucovorin for pediatric patients with malignant solid tumors. / Pratt, Charles B.; Meyer, William H.; Howlett, Nanna; Douglass, Edwin C.; Bowman, Laura C.; Poe, Debbie; Mounce, Kevin; Kun, Larry E.; Houghton, Janet A.

In: Cancer, Vol. 74, No. 9, 01.01.1994, p. 2593-2598.

Research output: Contribution to journalArticle

Pratt, CB, Meyer, WH, Howlett, N, Douglass, EC, Bowman, LC, Poe, D, Mounce, K, Kun, LE & Houghton, JA 1994, 'Phase II study of 5‐fluorouracil/leucovorin for pediatric patients with malignant solid tumors', Cancer, vol. 74, no. 9, pp. 2593-2598. https://doi.org/10.1002/1097-0142(19941101)74:9<2593::AID-CNCR2820740930>3.0.CO;2-C
Pratt, Charles B. ; Meyer, William H. ; Howlett, Nanna ; Douglass, Edwin C. ; Bowman, Laura C. ; Poe, Debbie ; Mounce, Kevin ; Kun, Larry E. ; Houghton, Janet A. / Phase II study of 5‐fluorouracil/leucovorin for pediatric patients with malignant solid tumors. In: Cancer. 1994 ; Vol. 74, No. 9. pp. 2593-2598.
@article{d36ae491c7924dd9a99a47b031df9886,
title = "Phase II study of 5‐fluorouracil/leucovorin for pediatric patients with malignant solid tumors",
abstract = "Background. 5‐Fluorouracil (5‐FU) activity for various carcinomas of adults has been enhanced through the synergistic effect of leucovorin. Few pediatric studies of 5‐FU in pediatric patients have been previously reported. Methods. Fifty‐eight patients were treated with a 4‐hour infusion of leucovorin, 400 mg/m2, administered daily for 5 days every 3‐4 weeks. 5‐Fluorouracil was administered by bolus injection 1 hour into each leucovorin infusion. Eleven adolescent patients with colorectal carcinoma, Stage 3 or 4, were treated with therapeutic intent, and other patients with a variety of drug‐resistant pediatric solid neoplasms received similar treatment. Results. Patients with measurable disease of colorectal carcinoma responded favorably to 5‐FU/leucovorin. Stable disease activity was seen with other tumor types. Specifically, there were no objective responses in 12 patients with Ewing's Sarcoma or 11 with osteosarcoma. There were 4 deaths in this study from causes related to toxicity. Nonfatal grade 3/4 toxicities included mucositis, rash, myelosuppression, nausea, vomiting, diarrhea, and infection. Conclusion. The authors do not plan further evaluation of 5‐FU/leucovorin in additional pediatric patients with colon cancer or other heavily pretreated malignant solid tumors and are presently treating their patients with colon carcinoma with 5‐FU/leucovorin/interferon‐α2a.",
keywords = "5‐Fluorouracil, childhood tumors, colon carcinoma, leucovorin",
author = "Pratt, {Charles B.} and Meyer, {William H.} and Nanna Howlett and Douglass, {Edwin C.} and Bowman, {Laura C.} and Debbie Poe and Kevin Mounce and Kun, {Larry E.} and Houghton, {Janet A.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19941101)74:9<2593::AID-CNCR2820740930>3.0.CO;2-C",
language = "English (US)",
volume = "74",
pages = "2593--2598",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Phase II study of 5‐fluorouracil/leucovorin for pediatric patients with malignant solid tumors

AU - Pratt, Charles B.

AU - Meyer, William H.

AU - Howlett, Nanna

AU - Douglass, Edwin C.

AU - Bowman, Laura C.

AU - Poe, Debbie

AU - Mounce, Kevin

AU - Kun, Larry E.

AU - Houghton, Janet A.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Background. 5‐Fluorouracil (5‐FU) activity for various carcinomas of adults has been enhanced through the synergistic effect of leucovorin. Few pediatric studies of 5‐FU in pediatric patients have been previously reported. Methods. Fifty‐eight patients were treated with a 4‐hour infusion of leucovorin, 400 mg/m2, administered daily for 5 days every 3‐4 weeks. 5‐Fluorouracil was administered by bolus injection 1 hour into each leucovorin infusion. Eleven adolescent patients with colorectal carcinoma, Stage 3 or 4, were treated with therapeutic intent, and other patients with a variety of drug‐resistant pediatric solid neoplasms received similar treatment. Results. Patients with measurable disease of colorectal carcinoma responded favorably to 5‐FU/leucovorin. Stable disease activity was seen with other tumor types. Specifically, there were no objective responses in 12 patients with Ewing's Sarcoma or 11 with osteosarcoma. There were 4 deaths in this study from causes related to toxicity. Nonfatal grade 3/4 toxicities included mucositis, rash, myelosuppression, nausea, vomiting, diarrhea, and infection. Conclusion. The authors do not plan further evaluation of 5‐FU/leucovorin in additional pediatric patients with colon cancer or other heavily pretreated malignant solid tumors and are presently treating their patients with colon carcinoma with 5‐FU/leucovorin/interferon‐α2a.

AB - Background. 5‐Fluorouracil (5‐FU) activity for various carcinomas of adults has been enhanced through the synergistic effect of leucovorin. Few pediatric studies of 5‐FU in pediatric patients have been previously reported. Methods. Fifty‐eight patients were treated with a 4‐hour infusion of leucovorin, 400 mg/m2, administered daily for 5 days every 3‐4 weeks. 5‐Fluorouracil was administered by bolus injection 1 hour into each leucovorin infusion. Eleven adolescent patients with colorectal carcinoma, Stage 3 or 4, were treated with therapeutic intent, and other patients with a variety of drug‐resistant pediatric solid neoplasms received similar treatment. Results. Patients with measurable disease of colorectal carcinoma responded favorably to 5‐FU/leucovorin. Stable disease activity was seen with other tumor types. Specifically, there were no objective responses in 12 patients with Ewing's Sarcoma or 11 with osteosarcoma. There were 4 deaths in this study from causes related to toxicity. Nonfatal grade 3/4 toxicities included mucositis, rash, myelosuppression, nausea, vomiting, diarrhea, and infection. Conclusion. The authors do not plan further evaluation of 5‐FU/leucovorin in additional pediatric patients with colon cancer or other heavily pretreated malignant solid tumors and are presently treating their patients with colon carcinoma with 5‐FU/leucovorin/interferon‐α2a.

KW - 5‐Fluorouracil

KW - childhood tumors

KW - colon carcinoma

KW - leucovorin

UR - http://www.scopus.com/inward/record.url?scp=0028081747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028081747&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19941101)74:9<2593::AID-CNCR2820740930>3.0.CO;2-C

DO - 10.1002/1097-0142(19941101)74:9<2593::AID-CNCR2820740930>3.0.CO;2-C

M3 - Article

C2 - 7923016

AN - SCOPUS:0028081747

VL - 74

SP - 2593

EP - 2598

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 9

ER -